IFNGR1 and Mendelian susceptibility to mycobacterial diseases: Management of the IFNGR1-related MSMD clinical spectrum varies by severity, with poor prognosis in the former case and infrequent need for prophylactic antibiotics or hematopoietic stem cell transplantation (HSCT) in the latter cases (Holland et al., 1998; Filipe-Santos et al., 2006).